A CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors

Chem Commun (Camb). 2023 Mar 21;59(24):3562-3565. doi: 10.1039/d2cc07076f.

Abstract

Low response rate limits the widespread application of cancer immunotherapy. To improve the response rate of immunotherapy, a CaCO3-based composite nanomaterial was developed to induce immunogenic cell death for enhancing immunotherapy against 4T1 primary and distal tumors.

MeSH terms

  • Cell Line, Tumor
  • Humans
  • Immunotherapy*
  • Neoplasms* / therapy